TD Asset Management Inc Sells 43,689 Shares of Zoetis Inc. $ZTS

TD Asset Management Inc cut its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 2.8% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,525,432 shares of the company’s stock after selling 43,689 shares during the quarter. TD Asset Management Inc’s holdings in Zoetis were worth $109,618,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in the business. J. Stern & Co. LLP boosted its holdings in shares of Zoetis by 12,431.2% in the 4th quarter. J. Stern & Co. LLP now owns 24,069,492 shares of the company’s stock worth $3,028,423,000 after buying an additional 23,877,416 shares during the last quarter. Norges Bank purchased a new stake in Zoetis during the fourth quarter worth about $734,425,000. Vanguard Group Inc. increased its holdings in Zoetis by 12.9% during the fourth quarter. Vanguard Group Inc. now owns 47,780,974 shares of the company’s stock worth $6,011,802,000 after buying an additional 5,474,210 shares during the last quarter. Ruane Cunniff & Goldfarb L.P. bought a new stake in Zoetis in the first quarter worth about $286,660,000. Finally, Van ECK Associates Corp raised its position in Zoetis by 269.0% in the fourth quarter. Van ECK Associates Corp now owns 2,387,059 shares of the company’s stock worth $300,340,000 after acquiring an additional 1,740,113 shares during the period. 92.80% of the stock is currently owned by institutional investors.

Zoetis Stock Performance

NYSE ZTS opened at $73.64 on Friday. The firm has a market cap of $30.43 billion, a P/E ratio of 12.13, a price-to-earnings-growth ratio of 1.31 and a beta of 0.74. The company has a quick ratio of 1.84, a current ratio of 3.08 and a debt-to-equity ratio of 2.87. The company’s 50 day moving average is $76.30 and its 200-day moving average is $99.01. Zoetis Inc. has a 12-month low of $71.45 and a 12-month high of $160.48.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Thursday, August 6th. The company reported $1.87 EPS for the quarter, topping the consensus estimate of $1.85 by $0.02. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. The company had revenue of $2.47 billion during the quarter, compared to the consensus estimate of $2.50 billion. During the same period last year, the firm earned $1.76 EPS. Zoetis’s revenue for the quarter was down .2% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. Sell-side analysts predict that Zoetis Inc. will post 6.19 earnings per share for the current year.

Zoetis Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Monday, July 20th will be issued a $0.53 dividend. This represents a $2.12 dividend on an annualized basis and a dividend yield of 2.9%. The ex-dividend date of this dividend is Monday, July 20th. Zoetis’s dividend payout ratio (DPR) is presently 34.93%.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the stock. BNP Paribas Exane reduced their target price on shares of Zoetis from $146.00 to $110.00 and set an “outperform” rating for the company in a research report on Tuesday. Argus reiterated a “hold” rating on shares of Zoetis in a research note on Wednesday, May 27th. Barclays reduced their price objective on Zoetis from $136.00 to $85.00 and set an “equal weight” rating for the company in a report on Wednesday, July 1st. JPMorgan Chase & Co. decreased their target price on Zoetis from $130.00 to $115.00 and set an “overweight” rating for the company in a research report on Friday, August 7th. Finally, Morgan Stanley set a $85.00 target price on Zoetis in a research note on Friday, August 7th. Eight investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $109.62.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.